Navigation Links
Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients
Date:8/29/2010

.

About Teriflunomide

Teriflunomide is a new oral disease modifier for RMS that blocks de novo pyrimidine synthesis thus reducing T- and B-cells proliferation with no cytotoxicity. A comprehensive clinical development program for teriflunomide has been launched in monotherapy. First Phase II study results of the safety and efficacy of teriflunomide monotherapy in MS were published in Neurology in 2006. In addition to the TEMSO trial, two other Phase III trials, TOWER and TENERE, are ongoing in RMS. A Phase III study, TOPIC, is also underway in early MS or Clinically Isolated Syndrome (CIS). Teriflunomide has also been evaluated as an adjunct therapy to either interferon 1-beta or glatiramer acetate in two Phase II studies. Results of these studies were presented earlier this year during the American Committee for Treatment and Research in Multiple Sclerosis meeting (ACTRIMS) congress, and the American Academy of Neurology (AAN) meeting respectively. Phase II studies with teriflunomide (7mg and 14mg) in adjunct with interferon 1-beta demonstrated an improvement in outcomes, with a consistent safety profile in patients treated with the adjunct treatment compared with patients treated with IFN-beta and receiving placebo. In the other Phase II study, teriflunomide in adjunct to glatiramer acetate (GA) was well-tolerated compared to patients receiving GA and placebo. Although there was a numerical trend for the reduction in number and volume of gadolinium enhancing T-1 brain MRI lesions in the adjunct arm compared to placebo with GA, the relative effect was not as robust as that observed for teriflunomide with IFN-beta.

About TEMSO Study

TEMSO is a 2-year randomized, double-blind, placebo controlled study including 1088 RMS patients worldwide, aged 18-55 years, with an Expanded Disability Status Scale (EDSS) <= 5.5 and at least one relapse over the previous year or at least 2 relapses over the preceding 2 years. Patients were randomized
'/>"/>

SOURCE Sanofi-aventis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Teriflunomide in Adjunct to Interferon Beta Significantly Improved Outcomes of Multiple Sclerosis Patients
2. Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice
3. Bucindolol Significantly Reduces Hospitalization and Death in Heart Failure Patients With Very Favorable Genotypes
4. Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery
5. Study Shows Machine Perfusion Significantly Improves Transplant Results
6. Epilepsia Study Demonstrates New Add-on Antiepileptic Drug Vimpat(R) (lacosamide) Significantly Reduces Partial-Onset Seizures in Adults With Epilepsy
7. New Multi-Center Study Finds Masimo SET Pulse Oximetry Screening Significantly Improves Detection of Congenital Heart Disease in Newborns
8. Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008
9. PROVENGE Significantly Prolongs Survival in Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
10. Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkins Lymphoma
11. Buehler Motor, Inc., Significantly Expands Customer and Partner Support in North America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... 2015 FLX Bio, Inc., a biopharmaceutical company ... immunotherapies, announced today that it has appointed Brian ... William Ho , M.D., Ph.D., as Chief Medical ... team led by veterans of Flexus Biosciences, Inc., FLX,s ... Officer; Jay Powers , Ph.D., Vice President, Drug ...
(Date:8/31/2015)... , Aug. 31, 2015 Trimb Healthcare AB ... to acquire YouMedical Group BV ("YouMedical"), a Dutch OTC ... total annual sales of approximately EUR 16 million, with ... "Our ambition is to build a leading ... step toward that goal. YouMedical gives us a stronger ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... ... together the world's most successful food and beverage processors, equipment manufacturers and leaders ... in product inspection and industrial weighing and formulation for manufacturers of bakery and ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... Proove Biosciences, ... County Technology Alliance Annual High Tech Awards. , Now in its 22nd year, ... products which drive innovation here, across the nation and around the world. The OC ...
Breaking Biology Technology:FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 2FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 3FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 4METTLER TOLEDO Hosts Food Safety Educational Center at 2015 PROCESS EXPO 2Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 2Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 3Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 4
... The Philadelphia area-based probiotics firm Kibow Biotech will be ... present at the BIO 2009 Company Forum, ... Tuesday, May 19. BIO is the world,s largest biotechnology ... more than 1,200 member companies and institutions worldwide. BIO ...
... announced that Chief Executive Officer, Mitchell H. Gold, M.D., ... Of The Year (R) 2009 Award in the ... the awards program recognizes entrepreneurs who demonstrate extraordinary success ... commitment to their businesses and communities. Mitchell Gold ...
... PAREXEL Consulting will present insights into achieving regulatory approval ... 18-21, 2009 at the Georgia World Congress Center in ... PAREXEL International (Nasdaq: PRXL ) and leading ... PAREXEL Consulting experts will be on site at the ...
Cached Biology Technology:Kibow Biotech, Inc. to Present at BIO 2009 International Convention: Innovations to Heal, Fuel, and Feed the World 2Kibow Biotech, Inc. to Present at BIO 2009 International Convention: Innovations to Heal, Fuel, and Feed the World 3Kibow Biotech, Inc. to Present at BIO 2009 International Convention: Innovations to Heal, Fuel, and Feed the World 4Dendreon Corporation CEO Mitchell H. Gold, M.D. Named Ernst & Young Entrepreneur of the Year(R) 2009 Award Finalist in the Pacific Northwest 2PAREXEL Consulting Experts To Present Insights Into Achieving Regulatory Approval at the 2009 BIO International Convention 2PAREXEL Consulting Experts To Present Insights Into Achieving Regulatory Approval at the 2009 BIO International Convention 3PAREXEL Consulting Experts To Present Insights Into Achieving Regulatory Approval at the 2009 BIO International Convention 4
(Date:8/12/2015)... CORAL SPRINGS, Florida , August 12, 2015 /PRNewswire/ ... globally, the pace of mobile payment innovation and advanced ... continues to replace the way consumers rely on using ... forges ahead with reinventing the future for payment services ... Inc. (NASDAQ: NXTD ), :  Google, Inc. (NASDAQ: ...
(Date:8/12/2015)... , Aug. 12, 2015  Synaptics Inc. ... human interface solutions, today announced that four of ... Match-in-Sensor solution, have officially been named FIDO Certified™ ... part of the certification, Synaptics, Natural ID™ fingerprint ... Universal Authentication Framework (UAF) standard and are interoperable ...
(Date:8/10/2015)... Germany , August 10, 2015 ... in Eye Tracking Technology for more than two decades, ... Platform for integration into all consumer display formats. The ... seamless integration of eye tracking into consumer tablets, laptops, ... reality smart glasses. Omnivision,s leading sensor technology contributes to ...
Breaking Biology News(10 mins):Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3
... issue of The American Naturalist, Tom E. X. Miller, ... the University of Nebraska, Lincoln) examined herbivore dynamics, specifically ... , Plant-insect ecologists typically attribute the differences to ... plant tissues. However, the researchers found that cactus-feeding insects ...
... role in longevity, with longer-lived rodents showing significantly lower ... new study has found. , The study further strengthens ... shorter its life, and vice versa, said Mario Pinto, ... regulate metabolic rate. , "Thyroid hormones are key ...
... international Census of Marine Life (CoML), a team of ... explore coral reef biodiversity in the largest fully protected ... National Monument. Led by the National Oceanic and ... funding from NOAA's Coral Reef Conservation Program and the ...
Cached Biology News:Longer-lived rodents have lower levels of thyroid hormone 2First Biodiversity Census of coral reef ecosystems in the NW Hawaiian Islands 2First Biodiversity Census of coral reef ecosystems in the NW Hawaiian Islands 3
... Timp-4 has been reported in heart ... fibroblasts in cell culture conditions. ... TPA stimulates production of TIMP-4 in ... protein levels produced often require concentration ...
Goat polyclonal to HSPC150 ( Abpromise for all tested applications). entrezGeneID: 29089...
Anti-MMP-13 Collagenase-3, amino terminal end of active enzyme; rabbit host...
...
Biology Products: